Ruthenium Complexes as Promising Candidates against Lung Cancer.

Abstract

Lung cancer is one of the most common malignancies with the highest mortality rate and the second-highest incidence rate after breast cancer, posing a serious threat to human health. The accidental discovery of the antitumor properties of cisplatin in the early 1960s aroused a growing interest in metal-based compounds for cancer treatment. However, the clinical application of cisplatin is limited by serious side effects and drug resistance. Therefore, other transition metal complexes have been developed for the treatment of different malignant cancers. Among them, Ru(II/III)-based complexes have emerged as promising anticancer drug candidates due to their potential anticancer properties and selective cytotoxic activity. In this review, we summarized the latest developments of Ru(II/III) complexes against lung cancer, focusing mainly on the mechanisms of their biological activities, including induction of apoptosis, necroptosis, autophagy, cell cycle arrest, inhibition of cell proliferation, and invasion and metastasis of lung cancer cells.

• Authors: Qi Sun, Yingsi Li, Hongdong Shi, Yi Wang, Jitian Zhang, Qianling Zhang
• Journal: Molecules (Basel, Switzerland) (Molecules) Vol. 26 Issue 15 (Jul 21 2021) ISSN: 1420-3049 [Electronic] Switzerland
• PMID: 34361543 (Publication Type: Journal Article, Review)

Chemical References

• Antineoplastic Agents
• Coordination Complexes
• Cytotoxins
• Ruthenium

Topics

• Animals
• Antineoplastic Agents (chemistry, therapeutic use)
• Coordination Complexes (chemistry, therapeutic use)
• Cytotoxins (chemistry, therapeutic use)
• Humans
• Lung Neoplasms (drug therapy, metabolism, pathology)
• Ruthenium (chemistry, therapeutic use)